Lamzede (Velmanase Alfa)

Velmanase Alfa is a recombinant human lysosomal alpha‑mannosidase. After intravenous infusion, it is taken up by cells via mannose‑6‑phosphate receptors and delivered to lysosomes, where it restores the missing enzymatic activity needed to break down mannose‑rich oligosaccharides, thereby decreasing their pathological accumulation.

The specific dose and infusion schedule of Lamzede are determined by the prescribing physician based on the patient’s age, weight, disease severity, and clinical response. Dosing is individualized and should follow the prescriber’s instructions.

Safety data for Lamzede in pregnancy and lactation are limited. The product’s pregnancy category is not established, so clinicians should weigh potential benefits against unknown risks and discuss options with the patient. Breastfeeding considerations should also be evaluated.

To request Lamzede, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and required import documentation.

Lamzede is a specific enzyme replacement therapy for alpha‑mannosidosis, whereas alternative approaches may include supportive care, symptomatic treatments, or investigational gene‑therapy strategies. Compared with non‑specific supportive measures, Lamzede directly addresses the underlying enzymatic deficiency, offering a disease‑modifying effect.

Lamzede must be stored refrigerated at 2‑8 °C, protected from light, and must never be frozen or shaken. The product should be kept in its original packaging until use to maintain stability and potency.

Lamzede is supplied as an injectable solution for intravenous infusion. The infusion is performed under medical supervision, typically over a period defined by the prescribing physician, with monitoring for infusion‑related reactions.

Serious risks include severe infusion‑related reactions such as anaphylaxis, significant hypotension, respiratory distress, and persistent hepatic enzyme elevation. Prompt recognition and management of these events are essential during and after the infusion.

Lamzede should be avoided in individuals with known hypersensitivity to velmanase alfa or any of its excipients. Caution is also advised for patients with uncontrolled cardiac disease, severe hepatic impairment, or those who have experienced severe infusion reactions to similar biologics.